Title |
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
|
---|---|
Published in |
Cochrane database of systematic reviews, September 2012
|
DOI | 10.1002/14651858.cd009159.pub2 |
Pubmed ID | |
Authors |
Sebastian Theurich<sup>a</sup>, Hans Fischmann<sup>a</sup>, Alexander Shimabukuro‐Vornhagen, Jens M Chemnitz, Udo Holtick, Christof Scheid, Nicole Skoetz<sup>a</sup>, Michael von Bergwelt‐Baildon<sup>a</sup> |
Abstract |
Allogeneic haematopoietic stem cell transplantation (HSCT) is an established treatment for many malignant and non-malignant haematological disorders. Graft-versus-host disease (GVHD), a condition frequently occurring after HSCT, is the result of host tissues being attacked by donor immune cells. One strategy for the prevention of GVHD is the administration of anti-thymocyte globulins (ATG), a set of polyclonal antibodies directed against a variety of immune cell epitopes, leading to immunosuppression and immunomodulation. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Netherlands | 1 | <1% |
Germany | 1 | <1% |
Unknown | 173 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 28 | 16% |
Student > Bachelor | 28 | 16% |
Researcher | 20 | 11% |
Student > Ph. D. Student | 17 | 10% |
Student > Postgraduate | 13 | 7% |
Other | 26 | 15% |
Unknown | 44 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 76 | 43% |
Nursing and Health Professions | 12 | 7% |
Biochemistry, Genetics and Molecular Biology | 8 | 5% |
Immunology and Microbiology | 7 | 4% |
Agricultural and Biological Sciences | 6 | 3% |
Other | 21 | 12% |
Unknown | 46 | 26% |